Highlights

  • Medibank (ASX:MPL) reported FY26 statutory NPAT of $638.7 million, up 27.5%, supported by higher Revenue and improved performance.
  • The company increased its full-year Dividend to 19.2 cents per share, fully franked, reflecting stronger earnings.
  • Medibank Health segment profit increased 31.3% to $100.7 million, supporting the group's Diversification strategy.
  • Investors remain focused on claims inflation, premium pricing, policyholder growth and the resolution of remaining regulatory matters.

Medibank (ASX:MPL) delivered a stronger FY26 result, supported by higher profit, increased Shareholder distributions and continued expansion of its health-services division. While insurance margins faced pressure from rising claims costs, the growing contribution from health services is becoming a more important part of the group's longer-term strategy. The key question for investors is whether Medibank can maintain Earnings growth while managing a more normalised claims environment.

From result-day weakness to renewed investor focus

Medibank Private (ASX:MPL) faced a mixed market reaction following its FY26 result, with investors initially focusing on softer insurance margins and higher claims pressure.

However, attention quickly shifted toward the company's defensive characteristics, including recurring premium revenue, higher earnings and growth in non-insurance health services.

The broader debate around Medibank has therefore moved beyond short-term Margin movements and toward whether the company can continue evolving from a traditional health insurer into a broader healthcare-services business.

The latest development: profit up, dividend up, health services growing

The FY26 financial performance showed improvement across several key areas.

Statutory net profit after tax increased 27.5% to $638.7 million, compared with $500.8 million previously.

Underlying NPAT was approximately $636.8 million, supporting a 6.7% increase in the total dividend.

The board declared a final dividend of 10.90 cents per share, fully franked, following the 8.30-cent interim dividend, bringing the full-year payout to 19.2 cents per share.

Group revenue excluding net Investment income increased 9.2% to $9,115.2 million.

The strongest growth came from Medibank Health, the company's non-insurance services division. Segment profit increased 31.3% to $100.7 million, with underlying organic growth estimated at around 20–25% excluding the impact of the Better Medical acquisition.

This division remains a key part of management's strategy to diversify earnings beyond traditional insurance.

Financial performance: margins versus claims

The main challenge within the result was the pressure on insurance margins.

Health Insurance revenue increased 8.0% to $8,652.2 million, but Health Insurance operating profit rose at a slower pace, increasing 3.8% to $769.8 million.

Resident claims expense increased 4.6%, while hospital claims per policy unit increased 40 basis points to 2.6%.

The increase reflects a return toward more normal claims conditions following unusually favourable periods during the pandemic.

Net investment income also declined by $28.9 million, with the underlying return easing 24 basis points to 5.62%.

Net tangible assets per share decreased to 56.7 cents from 62.7 cents, reflecting Capital management and investment mix changes.

Despite these pressures, the increase in dividends indicates confidence in the company's capital position.

Management expects FY27 expense growth of around 5.4%, consistent with FY26 levels, while also planning approximately $10 million of additional Marketing investment to support the Medibank brand.

What is driving the stock

Two opposing factors are shaping investor sentiment.

The positive case is based on Medibank's defensive characteristics.

Private health insurance provides recurring premium revenue, while annual premium approvals provide some pricing flexibility.

The growing health-services division also provides exposure to areas with different growth characteristics compared with traditional insurance.

On the other side, investors remain focused on insurance fundamentals.

Resident policyholder growth was modest at 1.1%, with the Medibank Brand increasing 0.6% and ahm rising 2.4%.

The company is also facing a less favourable claims environment as pandemic-related benefits continue to unwind.

For Medibank (ASX:MPL), the investment debate is increasingly centred on whether services growth can offset pressure from the core insurance business.

The growth story

Medibank's medium-term growth strategy has three main components.

First is profitable growth in private health insurance.

Management is focused on improving Market Share while maintaining pricing discipline and managing claims.

Second is Medibank Health.

Telehealth, in-home care and clinical services provide exposure to healthcare areas with potentially different growth drivers and lower reliance on traditional insurance underwriting.

Management expects continued growth from this segment, supported by expansion across healthcare services.

Third is capital returns.

Consistent fully franked dividends and potential future capital management initiatives remain important for income-focused investors.

If Medibank Health continues expanding and contributes a larger share of earnings, the overall Business mix could gradually become less dependent on insurance margins.

The risks

Claims Inflation remains the most immediate risk.

Hospital claims pressure in FY27 is expected to increase as the benefit from previous favourable claims conditions continues to unwind.

Premium-rate approvals are also controlled through government processes, limiting the company's ability to fully offset higher costs through pricing.

Slower policyholder growth could increase reliance on premium increases and cost control.

The 2022 cyberattack continues to represent a regulatory consideration, with an APRA supervisory capital adjustment of $250 million remaining subject to completion of the company's IT security uplift program.

Competition from other private health insurers remains intense, while potential regulatory action around affordability, pricing or industry settings could affect returns.

The company also faces execution risk as it expands its health-services platform and integrates new businesses.

What Investors Should Watch Next

Key areas to monitor include the FY27 premium-rate outcome, the trajectory of hospital claims inflation and progress toward resolving the remaining APRA capital overlay.

Investors should also watch Medibank Health's organic growth to assess whether diversification is becoming a more meaningful earnings contributor.

Policyholder growth across the core insurance brands will remain important, particularly as competition in private health insurance continues.

The half-year FY27 result, expected in February 2027, will provide further insight into whether insurance margins are stabilising or facing further pressure.

The Bottom Line

Medibank (ASX:MPL) delivered a solid FY26 result, with higher profit, increased dividends and strong growth from its health-services division.

The company's challenge is managing the transition from a period of unusually favourable claims conditions toward a more normalised insurance environment.

The long-term investment case increasingly depends on two factors: whether Medibank can maintain discipline in its core insurance business and whether its health-services expansion can continue adding value.

For investors, the defensive qualities remain intact, but claims inflation, premium settings and execution across the broader healthcare platform will determine the next phase of earnings growth.